{
    "2020-06-24": [
        [
            {
                "time": "",
                "original_text": "高瓴年内调研16家公司，刚刚入手广联达，接下来会买谁？",
                "features": {
                    "keywords": [
                        "高瓴",
                        "调研",
                        "广联达"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技",
                        "建筑信息化"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业半年度策略报告：紧抓“抗疫”和“自主定价”两大主线",
                "features": {
                    "keywords": [
                        "医药",
                        "抗疫",
                        "自主定价",
                        "策略报告"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "两大实控人身家超王健林，揭开医药股暴涨的面纱",
                "features": {
                    "keywords": [
                        "医药股",
                        "暴涨",
                        "实控人"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2020年中期策略：拥抱疫情后周期投资机会，重点关注医药新基建和医药大消费",
                "features": {
                    "keywords": [
                        "医药生物",
                        "疫情后周期",
                        "医药新基建",
                        "医药大消费"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2020年中期投资策略：坚持高景气赛道+龙头战略",
                "features": {
                    "keywords": [
                        "医药",
                        "高景气赛道",
                        "龙头战略"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}